Acción adyuvante de esporas de Bacillus subtilis por vía mucosal

TUB-CHAFER F.; REYES-DÍAZ LAURA; PEREZ OLIVER; GRAU R.

VacciMonitor

Finlay Ediciones

Año: 2016 vol. 25 p. 19 - 29

1025-0298

Bacillus subtilis spores generally considered safe, have received growing attention due to their potential biotechnological applications including vaccine formulations, particularly as vaccine adjuvants. In the present review we present the status of the adjuvanticity of the spore B. subtilis for mucosal route and our experience regarding its adjuvant activity induced against two model antigens, Tetanus Toxoid (TT) and ovalbumin (Ova) for oral (o.r) and intranasal (i.n) immunization. A document review on B. subtilis, adjuvant, vaccine and mucosal route was carried out in MEDLINE by PubMed, SciELO and LILACS databases. B. subtilis spores (RG 4365) were used for the exploration of the adjuvant activity. Balb/c mice were immunized by i.n and o.r route with TT or Ova combined with B. subtilis spores and specific antibody response in serum, saliva and fecal were measured by ELISA. This review showed the existence of several papers using B. subtilis spores as adjuvant by different methodologies and administration routes, being the expressionof recombinant antigens and the the o.r route the most widely used. In our work we found an increase of seric response of IgG, subclass IgG1 and IgG2a and specifi c IgA in saliva and feces in groups immunized with spores coadministered with Ova and TT by both routes, which was signifi cantly superior to control groups (p